Merck’s Ebola vaccine Ervebo is licensed to protect against a single species of the virus — but a new human study suggests it may also offer some protection against a different strain now fuelling one of the largest Ebola outbreaks on record.

The findings, published in the New England Journal of Medicine, come as the Democratic Republic of Congo battles a Bundibugyo ebolavirus outbreak in its northeastern region. Health authorities had recorded roughly 2,500 confirmed cases and about 1,000 deaths — the third-largest such outbreak documented, and the fastest-growing to date.

Why species matter for a vaccine

Ervebo is approved against the Zaire species, not Bundibugyo.

Several distinct ebolavirus species cause human disease, differing enough in their surface glycoprotein — the target of protective antibodies — that immunity to one is not assumed to cover another. Bundibugyo has historically caused a lower case fatality rate than Zaire, though the current outbreak is severe.

The vaccine works by using a modified livestock virus engineered to carry the Zaire glycoprotein, so the immune response it generates is directed at that specific protein. Whether antibodies raised against one species recognise another depends on how much of the protein is shared — which is an empirical question rather than a matter of principle.

What the data show

The same northeastern region saw more than 300,000 people vaccinated with Ervebo during a 2018–2020 Zaire outbreak, giving researchers a population to study.

Among confirmed cases with known vaccination history, nine people who had previously received Ervebo all survived. In one striking observation, three of eight exposed healthcare workers who had been vaccinated survived, while five unvaccinated colleagues died.

The researchers stress these are observational signals, not proof from a controlled trial.

How to read those numbers

The care in that framing is warranted, and the reasons are worth being explicit about.

Nine survivors out of nine is striking and involves nine people. With a case fatality rate below 100%, some survival among any nine patients would be expected, and a run of nine is not statistically remarkable on its own.

The healthcare worker comparison is more informative because it includes a contemporaneous unvaccinated group with similar exposure — and it too involves small numbers, and healthcare workers who accepted vaccination may differ from those who did not in ways affecting outcome, including access to care.

Survival is also a different endpoint from protection against infection. All nine were confirmed cases, meaning they were infected. If the vaccine helps, it appears to be by attenuating disease rather than preventing it.

Why the argument is for testing

“I believe we have now reached the point where this question should no longer be debated, it should be tested,” said Edouard Lhomme, the study’s first author and a professor at the University of Bordeaux.

That framing is the substance of the paper. The observational data are too weak to justify deploying the vaccine on the assumption it works, and strong enough to justify the effort of finding out.

Why it matters

With roughly 500,000 Ervebo doses in the international stockpile, a vaccine deployable against more than one Ebola species would be a meaningful tool in an outbreak still expanding.

The stockpile exists and is species-specific, so in a Bundibugyo outbreak it currently sits unused while an intervention that might help remains untested. That is the practical situation the authors are describing.

Why outbreak vaccine trials are hard to run

The call to test rather than debate is easy to endorse and difficult to execute, for reasons the Ebola field has confronted before.

An outbreak is unpredictable in location, size and duration. A conventional randomised trial requires enrolling enough people over enough time to detect an effect, and outbreaks frequently end before that is achieved — which is precisely what happened during the West African epidemic, where trials began as case numbers were already falling.

Randomising to placebo is also contested where a licensed vaccine exists for a related species and people are dying. That objection has real force even when the vaccine’s cross-protection is unproven.

The design developed in response is ring vaccination: identifying a confirmed case, tracing contacts and contacts of contacts, and randomising those rings to immediate or delayed vaccination. Everyone is vaccinated eventually, which addresses the ethical objection, and the comparison is between timing rather than between vaccine and nothing.

That approach generated the evidence behind Ervebo’s licensure, and it is the obvious template here — which is part of why the authors can reasonably describe the question as testable rather than merely open.

They are careful to frame their work as a case for formal testing — not a green light for off-label use. General information, not medical advice.